Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967343 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
A Phase 2 study, sponsored by Kiadis Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00967343 is a Phase 2 study that was terminated before completion, run by Kiadis Pharma. The registered enrollment target is 40 participants.
The verdict
NCT00967343, a Phase 2 study, was terminated before completion, sponsored by Kiadis Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related, haploidentical donor enhances survival by improving the immune effect against infections while preventing graft-versus-host disease .
Interventions
- BIOLOGICAL Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00967343
The ClinicalTrials.gov registry entry for NCT00967343 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiadis Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Donor lymphocyte preparation depleted of host functional alloreactive T-cells is the first listed.
NCT00967343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00967343 about?
NCT00967343 is a clinical study titled "Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor". The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related, haploidentical donor enhances survival by improving the immune effect against in...
What is the current status of trial NCT00967343?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2009-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00967343?
The interventions under investigation include: Donor lymphocyte preparation depleted of host functional alloreactive T-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00967343?
This trial is sponsored by Kiadis Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.